CognitiveInvestigational

N-acetyl Semax Amidate

Overview

N-acetyl Semax Amidate is a modified heptapeptide derivative of adrenocorticotropic hormone (ACTH) fragments, engineered with N-terminal acetylation and C-terminal amidation to enhance metabolic stability and blood-brain barrier penetration. It is believed to modulate brain-derived neurotrophic factor (BDNF) expression, enhance dopaminergic and serotonergic signaling, and improve cognitive performance and stress resilience. This analog exhibits prolonged activity compared to the parent Semax peptide.

Key Research Findings

Animal studies have demonstrated enhanced learning, memory consolidation, and neuroprotection in models of ischemia and cognitive deficit, with findings reported in neuroscience journals from the early 2000s. Limited human data exist, primarily from Russian clinical practice, with no large-scale randomized controlled trials published in international peer-reviewed literature. The peptide remains investigational outside Eastern Europe.

Route of Administration

Intranasal, Subcutaneous injection

Regulatory Status

Investigational

Interested in N-acetyl Semax Amidate?

Find a verified provider experienced with N-acetyl Semax Amidate protocols in your area. All providers are credentialed and use compliant sourcing.

Find a N-acetyl Semax Amidate Provider

Related Peptides

Semax

FDA Approved

A synthetic heptapeptide analog of the ACTH(4-7) fragment (Met-Glu-His-Phe-Pro-Gly-Pro) with nootropic and neuroprotective properties. Semax modulates BDNF and NGF expression, enhances monoaminergic neurotransmission, and provides neuroprotection through anti-oxidant and anti-inflammatory mechanisms. It crosses the blood-brain barrier via intranasal administration.

Selank

Investigational

A synthetic analog of the endogenous tetrapeptide tuftsin (Thr-Lys-Pro-Arg) with an added Pro-Gly-Pro sequence for stability. Selank exhibits anxiolytic activity comparable to benzodiazepines without sedation, dependence, or withdrawal effects. It modulates the expression of BDNF, serotonin, dopamine, and norepinephrine, and influences IL-6 and GABA receptor expression.

Cerebrolysin

Investigational

A porcine brain-derived peptide preparation consisting of low-molecular-weight neuropeptides and free amino acids that mimic the action of endogenous neurotrophic factors. Cerebrolysin exhibits neurotrophic activity similar to BDNF, GDNF, and CNTF, promoting neuronal survival, synaptic plasticity, and neurogenesis. It modulates GSK-3beta, CDK5, and calcineurin-NFAT signaling cascades involved in neurodegeneration.

P21 (Peptide)

Research Phase

A small synthetic peptide derived from the active region of ciliary neurotrophic factor (CNTF) designed to promote neurogenesis and synaptic plasticity. P21 is a tetrapeptide that crosses the blood-brain barrier and enhances dentate gyrus neurogenesis by increasing BDNF expression. Unlike full-length CNTF, P21 does not activate the JAK-STAT pathway or produce the anorectic and immunogenic effects of the parent protein.